Recent IPO activity in October 2026, including scheduled pricings for Iambic Therapeutics and City Therapeutics alongside recent completions by TRex Bio and Retension Pharmaceuticals, underscores an active pipeline of primarily biotech and smaller offerings. Equity market gains, with the Nasdaq Composite up over 35% year-to-date, have supported risk appetite and encouraged filings, though larger venture-backed names such as OpenAI and Anthropic continue to signal potential timelines extending into 2027 amid valuation considerations and regulatory scrutiny. Monetary policy stability and Treasury yield levels remain key variables influencing underwriter timing and investor demand for new issues through year-end.